Tumor Infiltrating Lymphocytes therapy(Essen Biotech)

N/A

Report date: 2026/04/17 10:36:36

Base Information

Drug NameTumor Infiltrating Lymphocytes therapy(Essen Biotech)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsBrain metastasesCarcinoma, Non-Small-Cell LungLung Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEssen Biotech
China Registration ClassN/A

Develop Information

Active CompaniesEssen Biotech
Inactive CompaniesN/A
Active IndicationsBrain metastasesCarcinoma, Non-Small-Cell LungLung Neoplasms +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A